Compare Ascendis Pharma A/S (ASND) vs Wix.Com Ltd (WIX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Wix.Com Ltd — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Wix.Com Ltd trades at $50.3 (market cap $2.10B). The key difference: Ascendis Pharma A/S is far larger — about 8.4× Wix.Com Ltd's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Wix.Com Ltd nearer its low. Which is the better fit depends on your goals.
| ASND | WIX | |
|---|---|---|
Market Cap | $17.74B | $2.10B |
Sector | Health | Technology |
52-Week High | $277.18 | $184.24 |
52-Week Low | $163.32 | $40.43 |
Enterprise Value | $18.11B | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Wix trades at $50.14, up 1.83% today, with a bearish technical signal despite recent earnings beats in Q3 and Q4 2025. Revenue grew to $1.99B in 2025, but net income margin remains negative at -1.97%. Recent news includes partnerships with Elavon and Microsoft, but multiple law firms are investigating potential securities fraud following a 27% stock drop in May 2026.
Analyst consensus is bullish with a $83.13 price target, but risks include ongoing fraud investigations, volatile cash flows, and negative shareholder equity. The stock faces headwinds from competitive pressures and execution risks despite strong revenue growth and institutional support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
